Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136679 · ClinicalTrials.gov registry record
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease
A clinical trial, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 95
- Enrollment target
NCT03136679: Completed study, sponsored by Baylor Research Institute.
NCT03136679 is a clinical trial that has completed, run by Baylor Research Institute. The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03136679 has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
Study Summary
This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center. The aim is to identify novel biomarkers that can distinguish normal aging subjects with no cognitive impairment from those with mild, moderate or severe cognitive impairment associated with Alzheimer's disease. Subjects will also be screened for B-vitamin deficiencies that may correlate with other metabolic biomarkers and Alzheimer's disease.
Primary Outcome
The primary goal of this proposal is to identify metabolic biomarkers in plasma and urine that can distinguish normal or mild cognitively impaired subjects from subjects at different severities of AD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2011-03-22 |
| Est. Completion | 2021-11-24 |
What the finished NCT03136679 record still lists
NCT03136679 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03136679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03136679 about?
NCT03136679 is a clinical study titled "Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease". This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center. The aim is to identify novel biomarkers that can distinguish normal aging subjects with no cognitive impairment from those with mild, moderate or severe cognitive ...
What is the current status of trial NCT03136679?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2011-03-22. Estimated completion is 2021-11-24.
Who is sponsoring clinical trial NCT03136679?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI